Southeast Asia is in the middle of a cancer surge. The eleven countries of the region recorded over 1.1 million new cancer cases in 2022, and the trajectory is steeply upward. The Asia-Pacific oncology market, valued at around USD 50 billion in 2024, is projected to reach USD 157 billion by 2033. Private operators — from specialist clinic groups to PE-backed healthcare platforms — are moving fast to capture this opportunity, and international players such as Icon Group are already opening new centres across Malaysia, Singapore, and Indonesia.
Behind the expansion narrative, however, lies a question that almost every operator and investor underestimates: what does it actually cost to treat a cancer patient, per year, across a full treatment journey?
It sounds like a basic financial question. In practice, it is one of the most analytically complex problems in all of healthcare finance — and getting it wrong has direct consequences for P&L forecasting, capital allocation, and investment underwriting.
The deceptive complexity of oncology economics
Most industries have relatively stable unit economics. Within healthcare, oncology sits in a category of its own — characterised by extreme treatment heterogeneity, multi-phase regimen structures, and a drug cost profile that can vary by orders of magnitude depending on tumour type, disease stage, and formulary choice.
Consider a basic comparison. A cervical cancer patient on standard platinum-based chemotherapy faces a very different annual drug cost from a lung cancer patient on a pembrolizumab-based immunotherapy combination. And within lung cancer, a patient who responds well and completes a full maintenance programme represents entirely different economics from one who discontinues after induction. These numbers are not close — they can diverge by multiples.
This is not imprecision. It reflects the genuine structure of oncology economics. Treatment unfolds in phases — induction, consolidation, maintenance — each with different drug combinations, cycle frequencies, and durations. The cost-driving drugs are typically biologics, targeted agents, or immunotherapies: classes where a single cycle can represent a substantial expense. Supporting drugs such as antiemetics and colony-stimulating factors are clinically necessary but financially negligible by comparison.
Then there is real-world treatment behaviour. In practice, patients discontinue early, experience toxicity requiring dose adjustments, progress to second-line therapy, or continue treatment beyond standard protocol duration. Each outcome produces a different economic footprint for the clinic.
Why standard financial modelling breaks down
The standard instinct when building a financial model is to start with the most detailed available data and aggregate upward. In oncology, this produces models that are technically impressive and operationally useless.
The problem is not data quality — clinical literature on treatment regimens is rich and precise. The problem is that clinical data is designed to answer clinical questions, not financial ones. Direct translation from protocol to model produces a structure that is too granular to be comparable across tumour types, too sensitive to clinical variation to produce stable outputs, and too opaque for the CEOs, investors, and CFOs who actually need to act on the numbers.
For ASEAN operators, the problem compounds further. Most published cost benchmarks and drug pricing assumptions are built around Western markets — the US, UK, and Western Europe. The drug prices, formulary structures, and utilisation patterns from those markets bear limited resemblance to private oncology clinics in Kuala Lumpur or Jakarta. An operator building financial plans on Western cost assumptions may be working from inputs that are structurally wrong for their market.
There is also a formulary dimension. The same tumour type can be treated with materially different drug combinations depending on market-specific approvals, prescribing culture, and patient access programmes. A financial model built around one formulary assumption can be substantially wrong when applied to a different geography or clinic context.
The methodology that actually works
Building a decision-useful oncology financial model requires a deliberate shift: away from clinical accuracy and toward financial decision-relevance. Several principles define the approach.
Standardise the patient, not the regimen. By fixing a consistent set of patient parameters — body surface area, weight, renal function — and holding them constant across calculations, a model creates a controlled basis for comparing the economics of different regimens and tumour types. This is an analytical convention, not a clinical prescription: it makes otherwise incomparable entities comparable, the same way financial benchmarking uses standardised inputs across companies.
Identify what actually drives cost. Across oncology regimens, a small number of drugs account for the overwhelming majority of economic impact. Biologics and targeted agents dominate. A model that accounts for every drug with equal weight is not more accurate — it is more cluttered. Deliberately excluding low-cost, non-material drugs is not a clinical compromise; it is a necessary step that makes outputs cleaner and more interpretable for non-clinical decision-makers.
Respect the multi-phase structure. Many regimens consist of distinct phases — induction and maintenance — that differ in drug composition, cycle length, and duration. This structure is the primary driver of treatment economics. Models that collapse phases into a single average cost figure lose the most important dimension of variability. A HER2-positive breast cancer patient on a trastuzumab-based protocol spends one phase on a triple-drug combination and another on trastuzumab monotherapy maintenance; these are economically distinct episodes and must be modelled separately.
Build in real-world utilisation. Protocol-based cost calculations tell you what treatment costs if every patient completes every cycle. In practice, patients drop out, and others continue beyond protocol. Capturing this requires a utilisation factor — a multiplier calibrated to real-world data where available, or to regional benchmarks where not.
Treat case mix as the master variable. For a multi-tumour clinic, the single most important driver of aggregate per-patient economics is not any individual regimen — it is the mix of patients across tumour types. A clinic weighted toward immunotherapy-intensive lung and HER2-positive breast presentations has materially different economics from one weighted toward cervical and colorectal cases. Case mix assumptions must sum to 100%, be grounded in realistic market data, and be subject to sensitivity analysis.
What this means in practice
At KPA, oncology financial modelling is a core part of our work for specialty clinic operators and healthcare investors across Southeast Asia. Every engagement is different — the specific tumour types, regimens, geographies, and strategic questions vary from project to project. What stays consistent is the methodology: a disciplined approach to translating clinical complexity into financial clarity, grounded in regional market knowledge and structured to produce outputs that are actually useful to decision-makers.
Oncology drug costs dominate the cost structure in a way that no other specialty matches. A unit economics error that seems small on paper — an underestimate of per-patient drug spend, a case mix assumption that proves incorrect, a failure to account for immunotherapy utilisation — compounds rapidly when a clinic is treating hundreds or thousands of patients per year. For investors, the same errors translate directly into valuation risk.
The financial analytical capability to translate clinical complexity into decision-useful models — calibrated to ASEAN formularies, pricing realities, and patient populations — remains relatively scarce in the region. That gap is where KPA operates.